Naratriptan Renata Pharmaceuticals (Ireland)

Naratriptan, the active ingredient in Naratriptan Renata Pharmaceuticals (Ireland), is a triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. GNH USA supplies Naratriptan Renata Pharmaceuticals (Ireland) as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan belongs to the triptan class and is used to treat acute migraine episodes.

- Migraine: provides relief of pain and associated symptoms during an acute migraine attack.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness or vertigo. - Fatigue: feeling unusually tired or weak. - Dry mouth: reduced salivation. - Tingling: transient paresthesia in extremities.

Serious or Rare Side Effects: - Chest pain: possible cardiac discomfort requiring immediate evaluation. - Serotonin syndrome: rare but severe condition with agitation, hyperthermia, and muscle rigidity. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hypertension: sudden increase in blood pressure. - Myocardial infarction: rare occurrence of heart attack symptoms.

Before using Naratriptan, consider the following precautions: - Cardiovascular disease: avoid if you have uncontrolled angina, recent myocardial infarction, or severe hypertension. - Stroke risk: contraindicated in patients with a history of cerebrovascular events. - Pregnancy: safety not established; discuss risks with a healthcare professional. - Breastfeeding: unknown safety; weigh benefits against potential risks. - Drug interactions: review concomitant serotonergic medications with your prescriber. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Naratriptan may interact with several medication classes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstrictive effects. - SSRIs/SNRIs: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible reduction in blood pressure control. - CYP3A4 inhibitors (e.g., ketoconazole): may raise naratriptan plasma levels. - Oral contraceptives: monitor for altered efficacy, though interaction is minimal.